2284621-75-4

2284621-75-4 structure

Name: JAK/HDAC-IN-1
Chemical Name: JAK/HDAC-IN-1
CAS Number: 2284621-75-4
Molecular Formula: C₁₉H₂₁Cl₂N₇O₂
Molecular Weight: 450.32
Catalog: Signaling Pathways Cell Cycle/DNA Damage HDAC
Create Date: 2019-06-02 01:15:55
Modify Date: 2024-01-22 10:23:56
JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively[1].

Name	JAK/HDAC-IN-1

Description	JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC Signaling Pathways >> Epigenetics >> HDAC
Target	JAK2:4 nM (IC50) JAK1:4.8 nM (IC50) JAK3:7.4 nM (IC50) Tyk2:49 nM (IC50) HDAC:2 nM (IC50) HDAC2:14 nM (IC50) HDAC6:120 nM (IC50) HDAC8:2470 nM (IC50)
In Vitro	JAK/HDAC-IN-1 (Compound 8m) exhibits IC50s of 4.8, 7.4 and 49 nM for JAK1, JAK3 and TYK2, and 14, 120, 2470 nM for HDAC2, HDAC6 and HDAC8, respectively[1].
References	[1]. Liang X, et al. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. J Med Chem. 2019 Apr 25;62(8):3898-3923.

Molecular Formula	C₁₉H₂₁Cl₂N₇O₂
Molecular Weight	450.32